Portal de Periódicos da CAPES

Chemotherapy-Related Nausea and Vomiting: Etiology and Management

1989; Wiley; Volume: 39; Issue: 2 Linguagem: Inglês

10.3322/canjclin.39.2.89

1542-4863

Gary R. Morrow,

Chemotherapy-related skin toxicity

CA: A Cancer Journal for CliniciansVolume 39, Issue 2 p. 89-104 ArticleFree Access Chemotherapy-related nausea and vomiting: Etiology and management Gary R. Morrow PhD, MS, Gary R. Morrow PhD, MS Associate Professor of Oncology in Psychiatry (Psychology) and Director of the Behavioral Medicine Unit at the University of Rochester Cancer Center in Rochester, New YorkSearch for more papers by this author Gary R. Morrow PhD, MS, Gary R. Morrow PhD, MS Associate Professor of Oncology in Psychiatry (Psychology) and Director of the Behavioral Medicine Unit at the University of Rochester Cancer Center in Rochester, New YorkSearch for more papers by this author First published: March/April 1989 https://doi.org/10.3322/canjclin.39.2.89Citations: 34AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Morrow GR: Management of nausea in the cancer patient, in S Rosenthal, JR Carignan, BD Smith (eds): Medical Care of the Cancer Patient. Philadelphia, WB Saunders Company, 1987, pp 381– 388. 2 Harris JG: Nausea, vomiting and cancer treatment. CA 28: 194– 201, 1978. 3 Durant JR: The problem of nausea and vomiting in modern cancer chemotherapy. CA 34: 2– 6, 1984. 4 Krakoff IH: Cancer chemotherapeutic agents. CA 37: 93– 105, 1987. 5 Hoagland AC, Morrow GR, Bennett JM, Carnrike CLM Jr: Oncologists' views of cancer patient noncompliance. Am J Clin Oncol 6: 239– 244, 1983. 6 Stuart-Harris R, Simes RJ, Coates AS, et al: Patient treatment preference in advanced breast cancer: A randomized cross-over study of doxorubicin and mitozantrone. Eur J Cancer Clin Oncol 23: 557– 561, 1987. 7 Olver IN, Simon RM, Aisner J: Antiemetic studies: A methodological discussion. Cancer Treat Rep 70: 555– 563, 1986. 8 CJ Davis, GV Lake-Bakaar, DG Grahame-Smith (eds): Nausea and Vomiting: Mechanisms and Treatment. Berlin, Springer-Verlag, 1986. 9 Laszlo J: Antiemetics and Cancer Chemotherapy. Baltimore, Williams and Wilkins, 1983. 10 Borison HL, Wang SC: Physiology and pharmacology of vomiting. Pharmacol Rev 5: 193– 230, 1953. 11 Borison HL, Borison R, McCarthy LE: Role of the area postrema in vomiting and related functions. Federation Proceedings 43: 2955– 2958, 1984. 12 Borison HL, McCarthy LE: Neuropharmacology of chemotherapy-induced emesis. Drugs 25: 8– 17, 1983. 13 Peroutka SJ, Snyder SH: Antiemetics: Neurotransmitter receptor binding predicts therapeutic actions. Lancet 1: 658– 659, 1982. 14 Harris AL: Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways. Lancet 1: 714– 716, 1982. 15 Kobrinsky NL, Pruden PB, Cheang MS, et al: Increased nausea and vomiting induced by naloxone in patients receiving cancer chemotherapy. Ped Res 21: 300A, 1987. 16 Seigel LJ, Longo DL: The control of chemotherapy induced emesis. Ann Intern Med 95: 352– 359, 1981. 17 Gralla RJ, Tyson LB, Kris MG, Clark RA: The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 71: 289– 301, 1987. 18 D'Acquisto RW, Tyson LB, Gralla RJ, et al: The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5: 257, 1986. 19 Sullivan JR, Leyden MJ, Bell R: Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309: 796, 1983. 20 Morrow GR: Susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy. Cancer Treat Rep 68: 1177– 1178, 1984. 21 Morrow GR: The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 55: 2766– 2770, 1985. 22 Gralla RJ, Braun TJ, Squillante A, et al : Metoclopramide: Initial clinical studies of high dosage regimens in cisplatin-induced emesis, in D Poster (ed): The Treatment of Nausea and Vomiting Induced by Cancer Chemotherapy. New York, Masson Publishing, 1981, pp 167– 176. 23 Morrow GR: Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 2: 1170– 1176, 1984. 24 Fetting JH, Wilcox PM, Iwata BA, et al: Anticipatory nausea and vomiting in a medical oncology clinic. Proc Am Soc Clin Oncol 2: 62, 1983. 25 Kris MG, Tyson LB, Gralla RJ, et al: Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 309: 433– 434, 1983. 26 Allen JC, Gralla RJ, Reilly L, et al: Metoclopramide: Dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 3: 1136– 1141, 1985. 27 Morrow GR, Morrell C: Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307: 1476– 1480, 1982. 28 Morrow GR: Effect of the cognitive hierarchy in the systematic desensitization treatment of anticipatory nausea in cancer patients: A component comparison with relaxation only, counseling and no treatment. Cognitive Therapy and Research 10: 421– 446, 1986. 29 Cassileth BR, Lusk EJ, Bodenheimer BJ, et al: Chemotherapeutic toxicity: The relationship between patients' pretreatment expectations and posttreatment results. Am J Clin Oncol 8: 419– 425, 1985. 30 Ettinger DS: The clinical use of antiemetics, in LR Derogatis (ed): Clinical Psychopharmacology. Redding, Mass, Addison Wesley, Inc, 1986, pp 248– 268. 31 Gralla RJ, Tyson LB, Bordin LA, et al: Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 68: 163– 172, 1984. 32 Carey MP, Burish TG, Brenner DE: Delta-9-tetrahydrocannabinol in cancer chemotherapy: Research problems and issues. Ann Intern Med 99: 106– 114, 1983. 33 Vincent BJ, McQuiston DJ, Einhorn LH, et al: Review of cannabinoids and their antiemetic effectiveness. Drugs 25: 52– 62, 1983. 34 Wampler G: The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 25 (suppl 1): 35– 51, 1983. 35 Morrow GR: Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. JNCI 68: 585– 588, 1982. 36 Burish TG, Carey MP, Redd WH, Krozely MG: Efficacy of behavioral relaxation techniques in reducing the distress of cancer chemotherapy patients. Oncol Nurs Forum 10: 32– 35, 1983. 37 Redd WH, Andrykowski MA: Behavioral intervention in cancer treatment: Controlling aversion reactions to chemotherapy. J Consult and Clin Psychol 50: 1018– 1029, 1982. 38 Morrow GR: Behavioral management of chemotherapy-induced nausea and vomiting in the cancer patient. The Clinical Oncologist 1: 3, 11– 14, 1986. 39 Morrow GR, Dobkin PL: Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions. Clin Psych Rev 8: 517– 556, 1988. Citing Literature Volume39, Issue2March/April 1989Pages 89-104 ReferencesRelatedInformation